Does Intensive Acid Suppression Reduce Esophageal Inflammation and Recurrent Barrett's Esophagus Following Ablation?

Completed · Phase 4

Conditions studied: Inflammation, Barrett's Esophagus

In brief

The investigators hypothesize that intensive acid suppression with a long acting high potency proton pump inhibitor (PPI) drug dexlansoprazole will lead to a greater decrease in levels of inflammatory mediators (compared to conventional PPIs) in the esophagus, which could potentially lead to decreased recurrence of intestinal metaplasia following endoscopic ablation.

Key facts

Study ID

NCT01093755

Run by

Mayo Clinic

People needed

30

Starts

2010-03-01

Expected to finish

2014-11-01

Last updated by the study team

2016-03-17

Who can join

Age: 18 and older, up to 90. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Absence of intestinal metaplasia on endoscopy (under Narrow Band Imaging) and on histology (from biopsies taken from gastroesophageal junction and distal esophagus) on two successive surveillance endoscopies.
• Able to consent to study
• Males and females age 18-90
• Life expectancy of 5 years or greater.

You may not qualify if…

• Pregnancy
• Inability to consent for the procedure
• Anticoagulation therapy precluding performance of ambulatory pH monitoring and/or biopsies
• Intolerance to proton pump inhibitors
• Elevation in Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), (liver enzymes), bilirubin or alkaline phosphatase more than five times the upper limit of normal.

Where it is running

• Mayo Clinic in Rochester — Rochester, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.